Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):67-83.
Goldenberg I, Moss AJ, Zareba W Sudden cardiac death without structural heart disease: update on the long QT and Brugada syndromes. Curr Cardiol Rep. 2005 Sep;7(5):349-56. Review.
Goldenberg I, Moss AJ Long QT syndrome. J Am Coll Cardiol. 2008 Jun 17;51(24):2291-300. doi: 10.1016/j.jacc.2008.02.068. Review.
Lane RD, Reis HT, Peterson DR, Zareba W, Moss AJ Happiness and stress alter susceptibility to cardiac events in Long QT Syndrome. Ann Noninvasive Electrocardiol. 2009 Apr;14(2):193-200. doi: 10.1111/j.1542-474X.2009.00295.x.
Malfatto G, Beria G, Sala S, Bonazzi O, Schwartz PJ Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. J Am Coll Cardiol. 1994 Feb;23(2):296-301.
Merri M, Moss AJ, Benhorin J, Locati EH, Alberti M, Badilini F Relation between ventricular repolarization duration and cardiac cycle length during 24-hour Holter recordings. Findings in normal patients and patients with long QT syndrome. Circulation. 1992 May;85(5):1816-21.
Moss AJ, Schwartz PJ 25th anniversary of the International Long-QT Syndrome Registry: an ongoing quest to uncover the secrets of long-QT syndrome. Circulation. 2005 Mar 8;111(9):1199-201. Review.
Moss AJ Clinical management of patients with the long QT syndrome: drugs, devices, and gene-specific therapy. Pacing Clin Electrophysiol. 1997 Aug;20(8 Pt 2):2058-60. Review.
Moss AJ Long QT Syndrome. JAMA. 2003 Apr 23-30;289(16):2041-4. Review.
Moss AJ Long QT Syndromes. Curr Treat Options Cardiovasc Med. 2000 Aug;2(4):317-322.
Moss AJ Management of patients with the hereditary long QT syndrome. J Cardiovasc Electrophysiol. 1998 Jun;9(6):668-74.
Moss AJ Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993 Aug 26;72(6):23B-25B. Review.
Moss AJ Prolonged QT-interval syndromes. JAMA. 1986 Dec 5;256(21):2985-7. Erratum in: JAMA 1987 Jan 23-20;257(4):487.
Moss AJ Sex hormones and ventricular tachyarrhythmias in LQTS: new insights regarding antiarrhythmic therapy. Heart Rhythm. 2012 May;9(5):833-4. doi: 10.1016/j.hrthm.2012.01.014. Epub 2012 Jan 20.
Moss AJ T-wave patterns associated with the hereditary long QT syndrome. Card Electrophysiol Rev. 2002 Sep;6(3):311-5. Review.
Moss AJ The long QT syndrome revisited: current understanding and implications for treatment. Pacing Clin Electrophysiol. 1997 Dec;20(12 Pt 1):2879-81.
Ning L, Moss AJ, Zareba W, Robinson J, Rosero S, Ryan D, Qi M Novel compound heterozygous mutations in the KCNQ1 gene associated with autosomal recessive long QT syndrome (Jervell and Lange-Nielsen syndrome). Ann Noninvasive Electrocardiol. 2003 Jul;8(3):246-50.
Vaglio M, Couderc JP, McNitt S, Xia X, Moss AJ, Zareba W A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology. Heart Rhythm. 2008 Jan;5(1):11-8. doi: 10.1016/j.hrthm.2007.08.026. Epub 2007 Aug 28.
Windle JR, Geletka RC, Moss AJ, Zareba W, Atkins DL Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvasive Electrocardiol. 2001 Apr;6(2):153-8.
Zareba W, Cygankiewicz I Long QT syndrome and short QT syndrome. Prog Cardiovasc Dis. 2008 Nov-Dec;51(3):264-78. doi: 10.1016/j.pcad.2008.10.006. Review.
Zareba W, Moss AJ, Konecki J TU wave area-derived measures of repolarization dispersion in the long QT syndrome. J Electrocardiol. 1998;30 Suppl:191-5.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.